

August 7, 2017



The Wistar Institute and ITUS Corporation Renew Collaborative Research Agreement

LOS ANGELES, CA -- (Marketwired) -- 08/07/17 -- ITUS Corporation (NASDAQ: ITUS) today announced that ITUS and The Wistar Institute have renewed their collaboration for the development of Cchek™, the company's early cancer detection technology.

Dr. Amit Kumar, ITUS's Chairman and CEO, stated, "We are pleased to continue our relationship with the Wistar Institute as we continue to advance our early cancer detection technology. Wistar's R&D support has been and continues to be valuable to the development of Cchek™."

Dr. Kumar continued, "Over the last two years working with Wistar, we have learned a great deal and have made significant advancements in our technology. We are utilizing artificial intelligence coupled with flow cytometry analysis of immune cells from an individual's blood, enabling us to identify tumor-bearing patients. As we are monitoring subtle changes in immune response of individuals, we expect this technology to be able to identify patients bearing any type of tumor. To date, we have demonstrated the efficacy of our technology in identifying 15 different tumor types and we are currently assessing which of these tumor types we will focus on for our first commercial effort."

The Wistar Institute, located in Philadelphia on the campus of the University of Pennsylvania, is an international leader in biomedical research with special expertise in cancer, immunology, infectious diseases and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972, holding an 'Exceptional' rating -- the highest possible ranking awarded.

ITUS Corporation

[ITUS](#), through its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the Cchek™ platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the

presence of a malignancy. Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION™

Contact:

Mike Catelani

(310) 484-5200

MCatelani@ITUScorp.com

Source: ITUS Corporation